411 related articles for article (PubMed ID: 20958231)
1. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
Seth S; Zanwar S; Vu L; Kapoor P
Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
[TBL] [Abstract][Full Text] [Related]
4. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
6. Prevention of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV
Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
9. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
Gámez B; Edwards CM
Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
[TBL] [Abstract][Full Text] [Related]
10. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
Kubiczkova L; Kryukov F; Slaby O; Dementyeva E; Jarkovsky J; Nekvindova J; Radova L; Greslikova H; Kuglik P; Vetesnikova E; Pour L; Adam Z; Sevcikova S; Hajek R
Haematologica; 2014 Mar; 99(3):511-8. PubMed ID: 24241494
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.
Thomsen H; Chattopadhyay S; Weinhold N; Vodicka P; Vodickova L; Hoffmann P; Nöthen MM; Jöckel KH; Langer C; Hajek R; Hallmans G; Pettersson-Kymmer U; Ohlsson C; Späth F; Houlston R; Goldschmidt H; Hemminki K; Försti A
Leukemia; 2019 Jul; 33(7):1817-1821. PubMed ID: 30737484
[No Abstract] [Full Text] [Related]
14. [Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis].
Hübel K; Hallek M
Internist (Berl); 2013 Jun; 54(6):709-14. PubMed ID: 23670732
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.
Awada H; Thapa B; Awada H; Dong J; Gurnari C; Hari P; Dhakal B
Cells; 2021 Aug; 10(8):. PubMed ID: 34440730
[TBL] [Abstract][Full Text] [Related]
17. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
Landgren O
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging in myeloma precursor disease.
Mena E; Choyke P; Tan E; Landgren O; Kurdziel K
Semin Hematol; 2011 Jan; 48(1):22-31. PubMed ID: 21232655
[TBL] [Abstract][Full Text] [Related]
19. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
